View in EDS

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Saved in:
Bibliographic Details
Title: Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Authors: Landen CN; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA., Buckanovich RJ; UPMC Hillman Cancer Center and Magee-Womens Research Institute and Foundation, Pittsburgh, PA., Sill MW; Clinical Trials Development Division, NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Mannel RS; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., Walker JL; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., DiSilvestro PA; Women & Infants Program in Women's Oncology, Providence, RI., Mathews CA; Women & Infants Program in Women's Oncology, Providence, RI., Mutch DG; Gynecologic Oncology, Washington University, St Louis, MO., Hernandez ML; Mercy Clinic Women's Oncology-Whiteside, Springfield, MO., Martin LP; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA., Bishop E; Froedtert & Medical College of Wisconsin, Milwaukee, WI., Gill SE; Gynecologic Oncology, SJC Oncology Services-Georgia, LLC, Savannah, GA., Gordinier ME; Norton Children's Hospital, Louisville, KY., Burger RA; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA., Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY., Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Moore KN; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK., Bookman MA; Department of Medical Oncology, Kaiser-Permanente Northern California, San Francisco, CA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 20; Vol. 42 (21), pp. 2537-2545. Date of Electronic Publication: 2024 May 22.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38776484
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Landen+CN%22">Landen CN</searchLink>; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA.<br /><searchLink fieldCode="AU" term="%22Buckanovich+RJ%22">Buckanovich RJ</searchLink>; UPMC Hillman Cancer Center and Magee-Womens Research Institute and Foundation, Pittsburgh, PA.<br /><searchLink fieldCode="AU" term="%22Sill+MW%22">Sill MW</searchLink>; Clinical Trials Development Division, NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY.<br /><searchLink fieldCode="AU" term="%22Mannel+RS%22">Mannel RS</searchLink>; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Walker+JL%22">Walker JL</searchLink>; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22DiSilvestro+PA%22">DiSilvestro PA</searchLink>; Women & Infants Program in Women's Oncology, Providence, RI.<br /><searchLink fieldCode="AU" term="%22Mathews+CA%22">Mathews CA</searchLink>; Women & Infants Program in Women's Oncology, Providence, RI.<br /><searchLink fieldCode="AU" term="%22Mutch+DG%22">Mutch DG</searchLink>; Gynecologic Oncology, Washington University, St Louis, MO.<br /><searchLink fieldCode="AU" term="%22Hernandez+ML%22">Hernandez ML</searchLink>; Mercy Clinic Women's Oncology-Whiteside, Springfield, MO.<br /><searchLink fieldCode="AU" term="%22Martin+LP%22">Martin LP</searchLink>; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Bishop+E%22">Bishop E</searchLink>; Froedtert & Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Gill+SE%22">Gill SE</searchLink>; Gynecologic Oncology, SJC Oncology Services-Georgia, LLC, Savannah, GA.<br /><searchLink fieldCode="AU" term="%22Gordinier+ME%22">Gordinier ME</searchLink>; Norton Children's Hospital, Louisville, KY.<br /><searchLink fieldCode="AU" term="%22Burger+RA%22">Burger RA</searchLink>; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Aghajanian+C%22">Aghajanian C</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.<br /><searchLink fieldCode="AU" term="%22Liu+JF%22">Liu JF</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Moore+KN%22">Moore KN</searchLink>; University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Bookman+MA%22">Bookman MA</searchLink>; Department of Medical Oncology, Kaiser-Permanente Northern California, San Francisco, CA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2024 Jul 20; Vol. 42 (21), pp. 2537-2545. <i>Date of Electronic Publication: </i>2024 May 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38776484
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.23.02076
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2537
    Titles:
      – TitleFull: Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Landen CN
      – PersonEntity:
          Name:
            NameFull: Buckanovich RJ
      – PersonEntity:
          Name:
            NameFull: Sill MW
      – PersonEntity:
          Name:
            NameFull: Mannel RS
      – PersonEntity:
          Name:
            NameFull: Walker JL
      – PersonEntity:
          Name:
            NameFull: DiSilvestro PA
      – PersonEntity:
          Name:
            NameFull: Mathews CA
      – PersonEntity:
          Name:
            NameFull: Mutch DG
      – PersonEntity:
          Name:
            NameFull: Hernandez ML
      – PersonEntity:
          Name:
            NameFull: Martin LP
      – PersonEntity:
          Name:
            NameFull: Bishop E
      – PersonEntity:
          Name:
            NameFull: Gill SE
      – PersonEntity:
          Name:
            NameFull: Gordinier ME
      – PersonEntity:
          Name:
            NameFull: Burger RA
      – PersonEntity:
          Name:
            NameFull: Aghajanian C
      – PersonEntity:
          Name:
            NameFull: Liu JF
      – PersonEntity:
          Name:
            NameFull: Moore KN
      – PersonEntity:
          Name:
            NameFull: Bookman MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 07
              Text: 2024 Jul 20
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 21
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1